SW
Swastik
Convolign Business Consulting LLP
In this article
Topics
Infectious disease diagnostics is one of the few areas of laboratory medicine where the commercial opportunity and the clinical urgency point in the same direction. Resistance is rising, pathogens keep emerging, and the tests that identify an infection quickly are the ones that determine whether treatment is targeted or guessed.
That does not make it an easy market to sell into. This guide maps the field for commercial teams: what infectious disease diagnostics covers, the technology layers and who buys each, what the market data does and does not tell you, how the UK is structured, and the route a new infection test has to travel before an NHS laboratory can use it. That last section is the one worth reading twice, because it is where most market entry plans turn out to be optimistic.
What Infectious Disease Diagnostics Covers
The field covers any test used to determine whether an infection is present, what is causing it, and how it should be treated. In practice that splits into four clinical questions, and they are not equally valuable.
- Is There An Infection? Distinguishing infection from other causes of the same presentation. Often the hardest question and the one with the least satisfying answers.
- What Is Causing It? Identifying the specific organism. The bulk of routine diagnostic activity.
- Will This Drug Work? Susceptibility and resistance, covered in depth in our guide to antibiotic susceptibility testing.
- Is It Spreading? Typing, sequencing and surveillance to detect transmission and outbreaks. Bought by public health rather than by hospitals.
Commercial teams frequently build products that answer the second question and pitch them as though they answered the third. Laboratories notice.
The Technology Layers
Infectious disease diagnostics is not one technology market. It is several, layered on top of each other, each with different buyers, price points and replacement cycles.
| Layer | What It Does | Time To Result | Primary Buyer |
|---|---|---|---|
| Culture and microscopy | Grows and identifies the organism; still underpins susceptibility testing | Days | Clinical microbiology |
| Immunoassay and antigen | Detects pathogen proteins or host antibodies | Minutes to hours | Microbiology, point of care, primary care |
| Molecular and PCR | Detects pathogen genetic material with high sensitivity | One to a few hours | Molecular laboratories, virology |
| Syndromic panels | Tests for many organisms at once around a presenting syndrome | About one hour | Microbiology with infection and stewardship input |
| Sequencing and genomics | Species identification, resistance prediction, transmission analysis | Days | Reference laboratories, UKHSA, public health |
| Host response and biomarkers | Measures the patient’s response rather than finding the pathogen | Minutes to hours | Acute medicine, intensive care |
| AI and informatics | Interprets, prioritises and connects results | Immediate | Pathology IT, digital and network leads |
The layers coexist rather than replace one another, which is the single most common misreading of this market. Molecular testing did not eliminate culture, because culture still delivers the full susceptibility profile. Sequencing did not eliminate molecular testing, because it is slower and sits in reference laboratories. A product strategy premised on displacing an entire layer usually underestimates why that layer still exists.
FutureDx Summit · London · 27-28 Oct 2026See The Infectious Disease Programme At FutureDxSepsis, drug-resistant TB, community screening, AI and precision medicine across two days in London.
How Large Is The Market, And Why Estimates Disagree
Published estimates of the global infectious disease diagnostics market vary enormously, and treating any single figure as authoritative is a mistake. The variation is not sloppiness. It reflects genuine differences in what is being counted.
- Whether COVID-19 Testing Is Included. Estimates spanning 2020 to 2022 include a volume of testing that has since collapsed, which produces both inflated baselines and alarming decline rates depending on the window chosen.
- Instruments Versus Consumables. Some models count placements, others count the recurring assay and reagent revenue that follows, which is where most of the value actually sits.
- Where The Boundary Sits. Whether sequencing, host response biomarkers, laboratory informatics and point of care testing are counted inside or outside the category.
The practical advice for a commercial or investment audience is to read the scope note before the headline number, and to build your own bottom up estimate for the specific segment and geography you are entering. A figure for the global market tells you very little about the addressable opportunity for a syndromic panel in English NHS microbiology.
The UK Picture
The UK is a disproportionately watched market because the NHS is a single large buyer with published data, which makes it useful as a reference case even for companies whose main revenue is elsewhere.
The scale is substantial. The 105 hospitals in England providing pathology services carry out around 1.12 billion tests a year across all disciplines. Those services have been consolidated into pathology networks, originally proposed as 29 with subsequent mergers leaving 27, each covering between three and eight hospital trusts on a hub and spoke model. Our guide to how NHS laboratory medicine is organised covers what that structure means for suppliers.
Two further features shape infection diagnostics specifically. Reference and specialist testing is centralised in UK Health Security Agency services, several of which are built on sequencing, as with the national mycobacterial service described in our guide to tuberculosis diagnostics. And the industry itself is represented by BIVDA, the not for profit trade association for the UK in vitro diagnostics sector, which is the body that engages with government on regulation and procurement.
How A New Infection Test Gets Adopted In The NHS
This is the section that matters commercially, and it is where optimistic plans meet reality. Adoption is not one decision. It is a sequence, and a product can fail at any stage while succeeding at all the others.
- Regulatory Approval. The device must be lawfully placed on the market. In Great Britain that means the UK Medical Devices Regulations 2002 and the UKCA mark, with CE marked devices currently still recognised. Our guide to IVDR and the UK regime covers this in detail.
- Health Technology Assessment. NICE evaluates diagnostics for clinical and cost effectiveness. Since 2022 it has also run an Early Value Assessment route for promising technologies where the evidence base is still emerging, and it is consolidating its previously separate diagnostics, medical technologies and interventional procedures programmes into a single HealthTech programme with a more rules based and predictable pathway to evaluation and funding.
- Funding. A positive assessment does not create a budget. Someone has to fund it, whether nationally, at network level, or by displacing existing spend.
- Network Procurement. Since consolidation, platform decisions are typically taken at pathology network level rather than by individual trusts, involving the network board, clinical leads, pathology IT and procurement.
- Local Verification. UKAS accreditation to ISO 15189 requires the laboratory to verify the method locally against its existing one before clinical use. This falls on laboratory staff and is a genuine barrier.
- Clinical And Stewardship Buy-In. For infection tests specifically, the antimicrobial stewardship team has effective veto, because a test that drives unnecessary antibiotic use will not be supported regardless of its performance.
The Realistic Timeline
Each of those stages involves different people, different evidence and different budgets, and they run sequentially more often than in parallel. A company planning a UK launch should assume a multi year path from regulatory clearance to routine use at network scale, and should be building relationships with clinical and laboratory leads well before the product is ready to sell.
FutureDx Summit · London · 27-28 Oct 2026Meet The NHS Buyers Who Evaluate Infection TestsSee the FutureDx delegate profile by job title and organisation.
Where The Commercial Opportunities Are
Reading the layers and the adoption route together points at where a new entrant realistically wins.
| Opportunity | Why It Is Open | Who You Have To Convince |
|---|---|---|
| Speed at the front of the pathway | Reference and confirmatory testing is well served; the gap is the first actionable answer | Acute clinicians, microbiology, infection control |
| Distinguishing infection from non-infection | Still poorly answered; host response approaches are early | Intensive care, acute medicine, stewardship |
| Decentralised and near-patient testing | Consolidation moved testing away from the patient, creating a turnaround gap | POCT coordinators, network leads, governance |
| Reducing hands-on time | Workforce pressure is persistent across laboratory medicine | Laboratory managers, network directors |
| Making existing data usable | Networks generate large volumes of results with limited interpretation capacity | Pathology IT, digital leads, clinical leads |
The recurring pattern is that the open opportunities are operational rather than purely analytical. The layers that already exist do the detection well. What they do less well is deliver an answer to the right person at the right time with acceptable staff effort.
FutureDx Summit · London · 27-28 Oct 2026Start The UK Conversations EarlyRequest the FutureDx sponsor pack for packages, audience detail and meeting formats.
Where FutureDx Summit Fits
FutureDx Summit 2026 is a two day conference dedicated to infectious disease and molecular diagnostics, held on 27 and 28 October 2026 at the Copthorne Tara Hotel London Kensington. It convenes 150+ validated NHS and industry decision-makers and is officially supported by BIVDA.
The programme covers the field rather than one corner of it, which is why it works as an orientation point for companies entering this market. Day 1 addresses sepsis diagnostics, drug resistant tuberculosis and blood borne virus screening in community settings. Day 2 moves to AI in diagnostics and precision medicine. The 23 confirmed speakers span the buying groups described above: Richard Vipond and Jean Lutamyo Mbisa, Deputy Directors at the UK Health Security Agency, for reference and genomics; Professor Adriana Calderaro of the University Hospital of Parma for clinical microbiology and virology; Peter Gayo Munthali for antimicrobial stewardship; Shazeena Hussain and Williams Tabowei for point of care testing; and Angela Douglas MBE and Helen Dent, President and Chief Executive of BIVDA, for the industry and regulatory view.
Sponsorship is organised by commercial objective, with routes for diagnostics companies generally, for AMR and sepsis diagnostics specifically, and for reaching infectious disease consultants. Packages include a defined number of pre-scheduled 1:1 meetings confirmed in advance, and the agenda covers both days.
What a focused conference does for a company entering this market is compress the relationship building described in the adoption section. It does not shorten NICE evaluation, create funding or guarantee adoption.
Frequently Asked Questions
What Is Infectious Disease Diagnostics?
Infectious disease diagnostics covers the tests used to determine whether an infection is present, identify the organism causing it, establish which drugs will treat it, and detect whether it is spreading. It spans culture and microscopy, immunoassays, molecular and PCR testing, syndromic panels, sequencing, host response biomarkers and the informatics that interpret the results.
What Technologies Are Used To Diagnose Infections?
Seven layers are in routine use: culture and microscopy, immunoassay and antigen testing, molecular and PCR testing, syndromic multiplex panels, sequencing and genomics, host response biomarkers, and AI and informatics. They coexist rather than replace one another, because each answers a different question at a different speed for a different buyer.
How Large Is The Infectious Disease Diagnostics Market?
Published estimates vary widely and should be read with their scope note. The main sources of variation are whether COVID-19 testing volumes are included, whether the model counts instrument placements or the recurring assay and reagent revenue, and whether sequencing, point of care testing and informatics fall inside the category. For commercial planning, a bottom up estimate for your specific segment and geography is more reliable than a global headline figure.
How Are New Infection Tests Adopted By The NHS?
Through a sequence rather than a single decision: regulatory approval under the UK Medical Devices Regulations with a UKCA mark, health technology assessment by NICE including its Early Value Assessment route, securing funding, procurement at pathology network level, local verification against ISO 15189 for UKAS accreditation, and clinical plus antimicrobial stewardship buy-in. A product can satisfy several of these stages and still fail at one.
Who Buys Infectious Disease Diagnostics In The UK?
Buying groups differ by technology layer. Routine microbiology and molecular testing is bought at pathology network level with input from clinical leads, laboratory managers and pathology IT. Point of care testing involves POCT coordinators and governance committees. Sequencing and surveillance sits with UK Health Security Agency reference services rather than with hospitals. For infection tests, antimicrobial stewardship teams are decisive.
What To Take From This
Infectious disease diagnostics rewards companies that understand it as several overlapping markets rather than one. The technology layers each persist for a reason, the buyers differ by layer, and in the UK the purchasing authority sits at network level while reference testing sits with national services.
The route to adoption is long and sequential, which has an unglamorous but important implication: the relationships that determine whether your product is evaluated at all are usually built years before the purchase order. That is the part of market entry most companies start too late.
FutureDx Summit · London · 27-28 Oct 2026Talk To The FutureDx Team About SponsorshipTell us which NHS and public health decision-makers you need to meet and we will send the full pack.